MISTR, the largest telemedicine provider offering free online PrEP and long-term HIV care in all 50 states, DC, and Puerto Rico, is now prescribing Doxycycline Post-Exposure Prophylaxis (DoxyPEP), an antibiotic that reduces bacterial STIs, including gonorrhea, chlamydia, and syphilis. Patients can now use MISTR’s seamless telehealth platform to receive DoxyPEP online for free.
With this launch, MISTR plans to further solve the issue of access and adherence to PrEP and HIV care, and now offers patients access to post-exposure care, in addition to their existing preventive and long-term HIV treatment options, which include PrEP and antiretroviral therapy (ART). This comes at a time when the rate of STIs continue to rise – in 2022, more than 2.5 million cases of syphilis, gonorrhea, and chlamydia were reported in the U.S; of that population, gay and bisexual men are disproportionately affected.
DoxyPEP has already shown promising results in reducing the rates of certain STIs. An NIH-funded study published by the New England Journal of Medicine in April 2023 found that doxycycline as post-exposure prophylaxis, now known as DoxyPEP, reduced syphilis by 87%, chlamydia by 88%, and gonorrhea by 55% in individuals taking HIV PrEP, and reduced syphilis by 77%, chlamydia by 74% and gonorrhea by 57% in people living with HIV. Now MISTR patients can receive DoxyPEP, in addition to their PrEP or HIV care medications.
This launch comes on the heels of immense growth for MISTR, with over 300,000 patients served. The company has plans to further expand their product portfolio in 2024 and open the doors to their MISTR storefronts. To learn more about MISTR, visit mistr.com.
